Rx for Biotech

In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.

EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.

Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.

In this episode of Rx for Biotech, host Chris Leidli sits down with Dr. Frank Bedu-Addo, CEO of PDS Biotechnology, to discuss how the company is reimagining immunotherapy with its proprietary Versamune® T-cell activating platform.

Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.

Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies.

In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.

In this podcast episode, Dr. Kilian Kelly, CEO of Cynata Therapeutics, discusses the future of regenerative medicine! Discover how mesenchymal stem cells (MSCs)—powerful cells that repair and regenerate tissues—are revolutionizing treatments for a range of diseases. Dr. Kelly shares insights on Cynata’s groundbreaking Cymerus™ platform and the exciting potential of MSC therapies.

Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.

AI is transforming job search, recruiting and hiring practices. Our guest in this podcast episode is Steve Swan, Practice Leader at The Swan Group. Steve is an Executive Recruiter specializing in technology for the Pharmaceutical and Biotech Industry. In this episode Steve shares his insights on how AI is transforming the hiring process.